|Application ||WB, E|
|Other Accession||Q925T8, Q920P3, Q7ZZR3, Q5E9L2|
|Predicted||Bovine, Chicken, Rat|
|Calculated MW||88760 Da|
|Antigen Region||85-111 aa|
|Other Names||BMP/retinoic acid-inducible neural-specific protein 1, Deleted in bladder cancer protein 1, BRINP1, DBC1, DBCCR1, FAM5A|
|Target/Specificity||This DBC1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 85-111 amino acids from the N-terminal region of human DBC1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||DBC1 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||DBC1, DBCCR1, FAM5A|
|Function||Inhibits cell proliferation by negative regulation of the G1/S transition. Mediates cell death which is not of the classical apoptotic type and regulates expression of components of the plasminogen pathway.|
|Tissue Location||Highly expressed in brain. Weakly expressed in heart, lung, skeletal muscle, kidney, thymus, prostate, testis and small intestine.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DBC1 is located within a chromosomal region that shows loss of heterozygosity in some bladder cancers. It contains a 5' CpG island that may be a frequent target of hypermethylation, and it may undergo hypermethylation-based silencing in some bladder cancers.
Koyama, S., et al. Biochem. Biophys. Res. Commun. 392(3):357-362(2010)
Gronbaek, K., et al. Mod. Pathol. 21(5):632-638(2008)
Louhelainen, J.P., et al. Oncogene 25(16):2409-2419(2006)
Izumi, H., et al. Hum. Mol. Genet. 14(8):997-1007(2005)
Beetz, C., et al. Oncol. Rep. 13(2):335-340(2005)
Nishiyama, H., et al. Oncogene 20(23):2956-2964(2001)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.